Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jenna Lambeth

Pain Medicine Belmont, NC Medical Doctor

NPI 1376860924 CMS profile 1334087

1212 Spruce St Ste 209, Belmont, NC 28012

Open in the dashboard

General payments

$10,526

145 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenna Lambeth of Belmont, NC is reported in the CMS Open Payments database as having received $10,526 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,411 41
2024 General $1,351 31
2023 General $5,782 40
2022 General $1,030 13
2021 General $825 15
2020 General $126 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenna Lambeth
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Jenna Lambeth were reported at $1,411. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Jenna Lambeth Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $126 $284 $80–$910 $114
2021 $825 $399 $112–$1,219 $132
2022 $1,030 $455 $137–$1,484 $149
2023 $5,782 $484 $128–$1,495 $160
2024 $1,351 $498 $131–$1,540 $164
2025 $1,411 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Abbott Laboratories $6,242 55 payments
  2. Relievant Medsystems, Inc. $1,081 9 payments
  3. SPR Therapeutics, Inc $945 22 payments
  4. Boston Scientific Corporation $630 21 payments
  5. Medtronic, Inc. $563 12 payments
  6. Nevro Corp. $296 6 payments
  7. Saluda Medical Americas, Inc. $231 3 payments
  8. Globus Medical, Inc. $197 4 payments
  9. Forte Bio-Pharma LLC $78 3 payments
  10. AbbVie, Inc. $72 3 payments
  11. Other $190 7 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $5,494 130 payments
  2. Travel and Lodging $5,032 15 payments
Products named General payments · program years 2020–2025
  1. PROCLAIM Neuromodulation $2,741 16 payments
  2. PROCLAIM Neuromodulation $2,431 11 payments
  3. Intracept Pain $1,081 9 payments
  4. SPRINT PNS System $945 22 payments
  5. Intracept Pain $907 7 payments
  6. Intracept Pain $907 7 payments
  7. Intracept Pain $907 7 payments
  8. WaveWriter Alpha Prime 16 $482 16 payments
  9. Proclaim IPG $438 8 payments
  10. ETERNA $281 7 payments
  11. Other $2,584 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

370

Median for Pain Management: 951

Drug cost

$5,201

Median for Pain Management: $26,034

Branded share of claims

18.4%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 39 $1,582
Gabapentin Generic 123 $1,104
Pregabalin Generic 35 $772
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 29 $681
Methocarbamol Generic 46 $449
Duloxetine Hcl Generic 13 $214
Tizanidine Hcl Generic 22 $142
Celecoxib Generic 17 $93
Tramadol Hcl Generic 14 $83
Methylprednisolone Generic 13 $50

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$92,081

Of which drugs: $232

Medicare patients

482

Average age 76

Services billed

2,980

287 women, 195 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Ischemic heart disease 31%
Depression 28%
Chronic kidney disease 25%
Atrial fibrillation 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 19 1,320 $136

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record